How to Group Multiple Models in One Submission for Overseas Registration of Home-Use Medical Devices

Key Summary

For overseas registration of home-use medical devices, the core of grouping multiple models in one submission is to reasonably group models based on the target country's regulatory framework, product risk classification, and technical differences. Companies should first determine whether the product falls within the scope of medical device regulation, then select the registration pathway based on risk class, and subsequently assess the reusability of existing NMPA, CE, FDA or other dossiers. The key to a grouped submission is to demonstrate that models within the same group are highly similar in basic principles, structural composition, intended use, and performance specifications, and that differences do not affect safety and effectiveness.

Companies need to prepare technical documentation, risk management reports, performance verification data, clinical evaluation or exemption justifications, and complete localization of labels and instructions for use, while appointing a local agent or authorized representative. Common risks include overly broad grouping leading to deficiency letters, incomplete technical files, unclear agent responsibilities, and lack of post-market maintenance. It is essential to clarify the target country list, grouping rationale, evidence chain, and agent agreement at the project outset to reduce duplicate work and amendment risks.

For Chinese medical device companies, a prudent approach is to first conduct product classification and documentation gap assessment, then determine whether existing NMPA, CE, FDA, ISO 13485 or other market dossiers can be reused. Target market registration usually simultaneously affects technical files, authorized representatives, importer coordination, label language, quality system certificates, and subsequent change maintenance. If the project is driven only by 'which documents to submit,' it is easy to encounter amendments or rework regarding model coverage, evidence chain consistency, label claims, and certificate control.

AIMEILI recommends that companies plan this issue within a broader GHWP member country and multi-country access strategy, using one set of reusable core technical files to support localization in different markets, rather than recreating dossiers from scratch for each country.

Applicable Scenarios and Core Issues

When registering home-use medical devices overseas, companies often face a practical question: if a series includes multiple models, must each model be registered separately? How can multiple models be grouped into one submission to save costs while ensuring compliance? This is not only a technical issue but also a regulatory strategy issue.

Typical scenarios include electronic blood pressure monitors, thermometers, home ventilators, blood glucose meters, and physiotherapy devices under the same brand with different specifications. These models may differ slightly in appearance, measurement range, or software functions, but their basic principles and intended uses are essentially the same.

If each model is registered individually, registration fees, testing time, and maintenance costs will inevitably increase. If models are blindly merged, however, the grouping may be rejected by regulatory authorities or require substantial supplementary data due to excessive differences. Therefore, companies must master the judgment logic and operational key points for grouped submissions.

The core issue is: how to define the boundary of a 'same group'? Different countries have different definitions and guidance on this, and companies must rely on the specific regulations and guidelines of the target market rather than experience alone.

Registration Judgment Logic

Step 1: Determine whether the product falls within the target country's medical device regulatory scope. Some home-use products, such as certain sports health monitoring devices, may not be considered medical devices and do not require medical device registration. Companies should make an initial judgment based on the target country's definitions and classification rules.

Step 2: Determine the risk classification. Home-use medical devices are usually low or medium-low risk, for example Class I or IIa in the EU, or Class II (requiring 510(k)) in the U.S. Risk class directly determines the registration pathway and depth of review.

Step 3: Assess the reusability of existing dossiers. If the company already has NMPA registration certificates, CE certificates, FDA 510(k) clearances, or ISO 13485 certificates, it should item-by-item review whether these documents are accepted by the target country or what localized documents need to be supplemented.

Step 4: Decide the grouping scheme based on technical differences. Generally, the conditions that allow grouping include: identical intended use, similar design and manufacturing process, same materials or key components, performance differences that do not affect safety and effectiveness, and differences within an acceptable range.

Step 5: Confirm the applicant entity and agent requirements. Most countries require overseas manufacturers to appoint a local agent or authorized representative and define its legal responsibilities. Whether the agent is qualified and whether the agreement is clear directly affects registration and subsequent maintenance.

Documentation and Evidence

Documents required for grouped submissions typically include: product family description, model comparison table, technical files, risk management reports, performance verification reports, biocompatibility reports (if applicable), software verification documents, label and instruction drafts, and clinical evaluation or exemption justifications.

The model comparison table is a core document. It should clearly list all models' specifications, functions, software versions, structural composition differences, and explain why the differences do not affect safety and effectiveness. This table should be prepared in the target country's official language or an accepted common language.

Technical files are recommended to follow the STED (Summary Technical Documentation) structure for reuse in multiple countries. The risk management report should comply with ISO 14971 and cover all models in the group.

Performance verification data must cover the 'worst-case' model in each group, i.e., the model with the worst performance or highest risk, to demonstrate that if that model passes, the other models are also covered.

Labels and instructions for use must be localized according to target country requirements, including language, units of measurement, warning symbols, and must list all covered models.

If the target country is a member of GHWP (Global Harmonization Working Party for Medical Devices), GHWP guidance may be referenced for document conversion, but each country retains its own local regulatory requirements and cannot be fully copied.

For multi-country registration, a 'core documentation set + localized files' strategy is recommended, establishing one set of core technical files and adding localized content per country to reduce duplicate work.

Common Mistakes

Companies often make the following mistakes in grouped submissions, which should be carefully avoided.

• Overly broad grouping: Forcing models with significantly different intended uses or technical principles into one group, leading to deficiency letters or rejections, causing delays.
• Insufficient evidence: Merely listing model differences without providing verification data proving that 'the differences do not affect safety and effectiveness' – lacking persuasiveness.
• Incorrect worst-case model selection: Failing to select the model with the worst performance or highest risk for testing, resulting in incomplete coverage logic.
• Lack of localization: Not translating labels and instructions for use according to target country requirements, or using different units of measurement, plug standards, etc.
• Unclear agent responsibilities: Failing to clarify the authorized scope, change reporting, adverse event reporting duties with the local agent, leading to post-market maintenance chaos.
• Neglecting post-market obligations: Failing to establish a post-market surveillance plan after registration, leading to certificate maintenance or renewal failure.

Company Preparation Checklist

To efficiently complete a grouped submission, companies should prepare the following items:

• Clarify the target country list and product classification, confirming whether the product is a medical device.
• Establish a series product model matrix, listing all models and their technical parameters.
• Determine the grouping logic based on target country regulations and GHWP guidelines.
• Prepare core technical files (STED format), including risk management and performance verification.
• Select the worst-case model and complete required testing and verification.
• Develop a localization plan for labels and instructions for use, complete translation and review.
• Appoint a qualified local agent or authorized representative, and sign an agreement with clear responsibilities.
• Establish post-market surveillance and adverse event reporting processes to ensure ongoing compliance.

AIMEILI's Perspective

The most common misjudgment in grouped submissions is assuming that 'all models are similar enough' to be grouped without the strict evidence chain required by target country regulators. If time is not invested upfront in compiling difference analyses, companies often face deficiency letters and delays later.

In the early stage of a project, two things should be prioritized: first, clarify the target market's grouping guidance; second, complete a model difference matrix and evidence mapping. This is more critical than rushing into testing or translation.

Among existing NMPA, CE, and FDA dossiers, technical files and risk management reports are usually reusable, but performance verification data, biocompatibility reports, and clinical evaluation conclusions may need updates due to different regulatory versions or applicable standards. Labels and instructions for use, as well as local agent documents, almost always require new localization and cannot be simply translated.

Local agent and certificate control are crucial. Many companies, after successful registration, are unable to update or transfer certificates due to agent changes or lack of cooperation. Companies should clearly specify in the agreement the ownership of the certificate, change procedures, and renewal responsibilities.

To reduce duplicate work and amendment risks in multi-country registration, the core is to establish a 'document master control plan,' centrally managing the differences across countries, using the same version of core technical files, and adding country-specific supplements as required. This improves efficiency and reduces the risk of omissions.

Frequently Asked Questions

Q: If models differ only in color, can they definitely be grouped in one submission?

A: Color differences generally do not affect safety and effectiveness. As long as they do not affect the function of use, they can usually be grouped together. However, the model comparison table and technical files should state the existence of color differences, and confirm whether the color materials have biocompatibility (e.g., if in contact with the human body). If the color materials release harmful substances, additional verification is still required.

Q: Does a grouped submission require test reports for every model?

A: No, not every model needs to be submitted individually. Usually, the test report for the worst-case model is sufficient, along with a rationale demonstrating coverage of all models. However, some countries may require differential testing for software features or specific performance of certain models, so companies should confirm this in advance.

Q: Can a single grouping scheme be uniformly used for multi-country registration?

A: Not completely. Different countries have subtle differences in the recognition of grouping and documentation requirements. For example, some Southeast Asian countries place more emphasis on local test data and local agent responsibilities, while Latin American countries may have stricter label requirements. It is recommended to base the approach on a core grouping scheme and then fine-tune it per country.

References and Applicability

Content compiled based on AIMEILI's registration practice question bank, medical device international registration knowledge base, and public regulatory information. Specific projects should be subject to the latest requirements of the target country's regulatory authority and the basis of the product documentation.

This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace official requirements, testing conclusions, or legal advice from the target country's regulatory authority.